EXAS—Question is if cumulative-sensitivity logic is appreciated by the FDA.
The answer is no, as noted at the bottom of my reply to iwfal in #msg-75642526.
The FDA wants a comparison to the gold standard-colonoscopy and if ColoGuard sensitivity and specificity in an individual test is only middling it won't pass like GIVN's 1st generation pill.
I fully agree.
A possible solution (maybe that's what EXAS is doing, please share if you know), is to perform each test on a few different samples for every individual with several repeats.
That should improve accuracy but only in case the DNA markers are real good. So another question is how good are their markers?
That’s the $64,000 question. EXAS has done a lot of work in this regard and is still doing more (to potentially upgrade the assays) concurrently with running the DEEP-C study—see http://www.clinicaltrials.gov/ct2/show/NCT01260168.
All told, EXAS’ ColoGuard is a fairly high-risk program, IMO; however, there’s a very compelling medical need for something better, more tolerable, and less invasive than standard or virtual colonoscopy (even with the no-prep software enhancements). GIVN’s PillCam COLON 2 could play a role in this market, but it hardly seems like the ultimate solution.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.